01—Abstract
Summary
Summary of the 10-Q filed October 22, 2024. Cited figures are marked; the original filing is the authoritative source.
Danaher's third-quarter 2024 10-Q shows a quarter where top-line growth was modest but profitability fell sharply, driven largely by a non-cash impairment.
Q3 sales rose 3.0% to $5.80 billiona, with core sales up only 0.5% and acquisitions adding 2.5%. Operating profit fell 19% to $958 million, and operating margin compressed 460 basis points to 16.5%. Diluted EPS from continuing operations was $1.12, down from $1.26.
The margin decline was driven primarily by a $222 millionb pretax trade name impairment in the Life Sciences genomics consumables business, plus dilution from acquisitions and weaker Life Sciences core sales. For the nine months, sales declined 1.0% to $17.34 billion and core sales fell 2.0%, led by a roughly 8.5% core decline in Biotechnology as customers worked down inventory. Diagnostics was the bright spot, with core sales up 5.0% and operating margin up 410 basis points to 28.0%.
Net earnings from continuing operations were $2.81 billionc, down from $3.10 billion. Operating cash flow was $4.67 billion, and the company returned substantial capital, repurchasing about $5.2 billion of common stock and paying $573 million in dividends. The balance sheet remains substantial but is less liquid.
Cash fell to $2.6 billiond from $5.9 billion at year-end 2023, and total debt declined to $17.5 billion. Management expects the bioprocessing business to return to high-single-digit core growth in Q4 2024 while full-year bioprocessing core sales decline at a low-single-digit rate. The company also flagged softness in genomics and weaker demand from smaller biopharma customers as ongoing risks.
02—Key points
Key Highlights
- Q3 2024 sales rose 3.0% to $5.80B, but core sales grew only 0.5%; acquisitions contributed 2.5 points of growth.
- Q3 operating profit fell 19% to $958M and operating margin dropped 460 bps to 16.5%, including a $222M pretax trade name impairment in Life Sciences genomics consumables.
- Diluted EPS from continuing operations was $1.12 for Q3 (vs. $1.26) and $3.80 for the nine months (vs. $4.15).
- Nine-month core sales declined 2.0%, with Biotechnology core sales down 8.5% while Diagnostics core sales grew 5.0% and its operating margin rose to 28.0%.
- Danaher repurchased about $5.2B of common stock in the first nine months, reducing cash to $2.6B from $5.9B at year-end 2023.
- Operating cash flow from continuing operations was $4.67B for the nine months, down 5% year over year.
- Management expects Q4 2024 bioprocessing core growth in the high-single digits but a full-year bioprocessing core decline in the low-single digits; a new 20M-share buyback authorization was approved in July 2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Danaher Corp kept $0.14.
- Revenue$5.80B100.0%
- Cost of revenue−$2.40B41.3%
- Gross profit$3.40B58.7%
- Operating costs−$2.44B42.1%
- Operating income$958.0M16.5%
- Interest, other & tax−$140.0M2.4%
- Net income$818.0M14.1%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 22, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $5.80B$5.62B | +3.1% |
| Cost of Revenue | $2.40B$2.35B | +2.0% |
| Gross Profit | $3.40B$3.27B | +3.8% |
| R&D Expenses | $383.00M$362.00M | +5.8% |
| SG&A Expenses | $2.06B$1.73B | +19.2% |
| Operating Income | $958.00M$1.19B | −19.2% |
| Net Income | $818.00M$1.13B | −27.5% |
| EPS (Basic) | $1.13$1.53 | −26.1% |
| EPS (Diluted) | $1.12$1.51 | −25.8% |
| Shares Outstanding (Basic) | 723.00M739.40M | −2.2% |
| Shares Outstanding (Diluted) | 729.40M745.90M | −2.2% |
05—Questions
Frequently Asked Questions
Why did Danaher's operating margin fall so sharply in Q3 2024?
Operating margin fell 460 basis points to 16.5%, primarily due to a $222M pretax non-cash impairment of an indefinite-lived trade name in the Life Sciences genomics consumables business (about 385 bps of the decline). Acquisition-related dilution (about 120 bps) and weaker Life Sciences core sales also contributed, partly offset by higher Diagnostics core sales and cost improvements.
How is the Biotechnology segment performing?
Biotechnology is under pressure. Nine-month segment sales fell 9.5% and core sales fell 8.5%, as customers reduced inventory levels. Bioprocessing returned to core growth in Q3 on larger customers, but smaller customers remain weak. Management expects high-single-digit core growth in Q4 2024 but a low-single-digit core decline for full-year 2024 bioprocessing.
Is Danaher's balance sheet still strong after the share repurchases?
The company remains in compliance with all debt covenants and has about $2.6B in cash, with roughly $2.2B held outside the U.S. Total debt fell to $17.5B from $18.4B, partly through repayment of a €900M note in April 2024. Shareholders' equity declined to $51.3B from $53.5B, reflecting the buybacks, and the company says it has sufficient liquidity for its cash needs.
What is driving the Diagnostics segment's strength?
Diagnostics grew core sales 5.0% in both the three- and nine-month periods, led by North American molecular diagnostics (including respiratory tests) and clinical lab demand. Nine-month operating margin rose to 28.0% from 23.9% on higher sales and cost improvements, making it the company's most profitable and fastest-growing segment in the period.
What does the 10-Q say about the outlook for the rest of 2024?
The filing gives limited formal guidance, but it sets an expected effective tax rate of about 17.5% for the rest of 2024 and notes that the bioprocessing recovery is expected to continue gradually. It also says the genomics market is soft and that high-growth markets, especially China, face weak demand. Investors should watch whether Life Sciences and Biotechnology core sales stabilize.
06—Continue